Chapter review

Must know

• Delusion subtypesDelusions are fixed false beliefs that persist despite conflicting evidence and represent 1 of the 5 core psychotic feature domains in the schizophrenia spectrum.

  • Delusions are fixed false beliefs that persist despite conflicting evidence and represent 1 of the 5 core psychotic feature domains in the schizophrenia spectrum.
  • The 6 primary delusion subtypes are persecutory (most common overall), referential, grandiose, erotomanic, nihilistic, and somatic.
  • Delusions are classified as bizarre if they are physically impossible (such as alien abduction or organ removal without surgical scars) or non-bizarre if they involve plausible real-life scenarios (such as being spied on by police or cheated on by a partner).
  • Under DSM-5-TR Criterion A for schizophrenia, at least 1 of the 2 required active symptoms must be delusions, hallucinations, or disorganized speech.
  • Active psychotic symptoms must persist for at least 1 month, within a total continuous disturbance timeline of at least 6 months.
  • Delusional disorder requires 1 or more delusions lasting for at least 1 month without marked social or occupational impairment outside the specific impact of the delusion.
• Five Core Psychotic DomainsPsychosis involves clinical abnormalities across 5 primary feature domains: delusions, hallucinations, disorganized thinking (formal thought disorder), grossly disorganized or abnormal motor behavior (including catatonia), and negative symptoms.

  • Psychosis involves clinical abnormalities across 5 primary feature domains: delusions, hallucinations, disorganized thinking (formal thought disorder), grossly disorganized or abnormal motor behavior (including catatonia), and negative symptoms.
  • Delusions and hallucinations represent positive symptoms that reflect added pathological features during the active phase of illness.
  • Disorganized thinking is inferred directly from formal speech patterns, presenting as derailment, loose associations, or tangentiality.
  • Grossly disorganized motor behavior ranges from catatonic immobility to aimless agitation that disrupts daily self-care and activities of daily living.
  • Negative symptoms reflect functional deficits, primarily diminished emotional expression (flat affect) and avolition (loss of self-initiated purposeful activity), which emerge in prodromal and residual phases and drive long-term disability.
• Delusion Subtypes and Clinical FeaturesPersecutory delusions: The patient holds a fixed belief that they are being harmed, spied on, harassed, poisoned, or conspired against by external forces. This is the most prevalent delusion subtype in schizophrenia.

  • Persecutory delusions: The patient holds a fixed belief that they are being harmed, spied on, harassed, poisoned, or conspired against by external forces. This is the most prevalent delusion subtype in schizophrenia.
  • Referential delusions: The patient believes that neutral environmental events, public comments, television broadcasts, newspaper articles, or gestures from strangers have a direct, hidden personal meaning meant specifically for them.
  • Grandiose delusions: The patient believes they possess exceptional abilities, unacknowledged talent, supreme wealth, fame, or a special relationship with a deity or famous persona.
  • Erotomanic delusions: The patient falsely believes that another individual, usually a person of higher social standing, celebrity status, or authority, is deeply in love with them.
  • Nihilistic delusions: The patient maintains a conviction that a major impending catastrophe will destroy the world, or that they themselves, their organs, or society no longer exist.
  • Somatic delusions: The patient is preoccupied with ungrounded beliefs concerning bodily functions, physical health, or severe internal organ decay despite normal medical evaluations.
• Diagnostic Timelines and Differential ComparisonSchizophrenia: Requires 2 or more Criterion A symptoms for at least 1 month (with at least 1 being delusions, hallucinations, or disorganized speech) and continuous disturbance signs lasting at least 6 months, accompanied by marked social or occupational decline.

  • Schizophrenia: Requires 2 or more Criterion A symptoms for at least 1 month (with at least 1 being delusions, hallucinations, or disorganized speech) and continuous disturbance signs lasting at least 6 months, accompanied by marked social or occupational decline.
  • Delusional disorder: Features 1 or more delusions lasting longer than 1 month. Crucially, social and occupational functioning is preserved outside the specific impact of the delusion, and core schizophrenia features like hallucinations or negative symptoms are absent or minimal.
  • Brief psychotic disorder: Features acute psychotic symptoms lasting from 1 day to less than 1 month, followed by a complete return to premorbid functioning.
  • Schizophreniform disorder: Features active schizophrenia symptom criteria lasting at least 1 month but less than 6 months, without requiring demonstrated social or occupational decline.
• Safety AlertActive persecutory delusions or command auditory hallucinations in unmedicated patients elevate the risk of defensive agitation or violent outbursts. Conduct immediate risk assessments for harm to self or others.

  • Active persecutory delusions or command auditory hallucinations in unmedicated patients elevate the risk of defensive agitation or violent outbursts. Conduct immediate risk assessments for harm to self or others.
  • Suicide is attempted by 20% to 50% of individuals with schizophrenia, with a 5% lifetime completed suicide rate. Key risk factors include co-occurring major depressive episodes, command hallucinations, substance use, and preserved insight into functional deficits.
  • Rule out organic medical etiologies (such as central nervous system tumors, temporal lobe epilepsy, HIV/AIDS, neurosyphilis, hypercalcemia, or steroid toxicity) before diagnosing primary psychosis.
• Board TrapDo not mistake delusional disorder for schizophrenia. Patients with delusional disorder maintain normal functioning, grooming, and logic outside their specific delusional focus.

  • Do not mistake delusional disorder for schizophrenia. Patients with delusional disorder maintain normal functioning, grooming, and logic outside their specific delusional focus.
  • Do not pathologize culturally or religiously sanctioned beliefs. For instance, experiencing brief contact with the spirit of a recently deceased relative in accordance with cultural tradition is not a psychotic delusion.
• First-LineFirst-episode psychosis warrants immediate referral to coordinated specialty care (CSC) programs to combine pharmacotherapy, psychotherapy, family education, and employment support.

  • First-episode psychosis warrants immediate referral to coordinated specialty care (CSC) programs to combine pharmacotherapy, psychotherapy, family education, and employment support.
• Hallucinations vs normal statesHallucinations are vivid, clear perceptions occurring without an external stimulus that are not under voluntary control, with auditory hallucinations being the most common form in schizophrenia.

  • Hallucinations are vivid, clear perceptions occurring without an external stimulus that are not under voluntary control, with auditory hallucinations being the most common form in schizophrenia.
  • Hypnagogic (falling asleep) and hypnopompic (waking up) hallucinations occur during normal sleep-wake transitions and represent non-psychotic physiological phenomena.
  • DSM-5-TR diagnosis of schizophrenia requires at least 2 characteristic symptoms for a 1-month active phase, and at least 1 symptom must be delusions, hallucinations, or disorganized speech.
  • Continuous signs of disturbance in schizophrenia must persist for at least 6 months, whereas brief psychotic disorder lasts 1 day to less than 1 month, and schizophreniform disorder lasts 1 month to less than 6 months.
  • Non-psychotic visual hallucinations in elderly patients with vision loss from macular degeneration or diabetic retinopathy represent Charles Bonnet syndrome, where patients remain alert, lucid, and aware the images are not real.
  • Culturally sanctioned experiences, such as perceiving or communicating with a recently deceased loved one during normal grief, are non-pathological and do not constitute a psychotic disorder.
• Five Core Psychotic Domains and Hallucination MechanicsHypnagogic hallucinations occur while falling asleep.

  • Hypnagogic hallucinations occur while falling asleep.
  • Hypnopompic hallucinations occur while waking up.
  • Both hypnagogic and hypnopompic experiences occur during normal sleep-wake transitions and must never be diagnosed as primary psychosis or schizophrenia.
• Auditory Hallucinations in SchizophreniaThink: True primary psychotic perception.

  • Think: True primary psychotic perception.
  • Priority: Assess for command content and immediate safety risk.
  • Boards are testing: Required core diagnostic criterion for schizophrenia requiring at least a 1-month active phase within a 6-month total disturbance.
• Hypnagogic and Hypnopompic HallucinationsThink: Normal sleep-wake transition phenomena.

  • Think: Normal sleep-wake transition phenomena.
  • Priority: Reassure patient; no psychotropic intervention required.
  • Boards are testing: Differentiating normal neurophysiology from primary psychiatric pathology.
• Charles Bonnet SyndromeThink: Release visual hallucinations secondary to ocular vision loss.

  • Think: Release visual hallucinations secondary to ocular vision loss.
  • Priority: Ophthalmologic evaluation and patient reassurance.
  • Boards are testing: Medical mimic of visual hallucinations in elderly patients with preserved insight and cognition.
• Culturally Sanctioned Bereavement ExperiencesThink: Culturally normative grief response.

  • Think: Culturally normative grief response.
  • Priority: Validate cultural context; avoid premature psychotropic prescribing.
  • Boards are testing: Avoiding false-positive diagnoses of brief psychotic disorder.
• Positive Symptoms versus Negative SymptomsThink: Added pathological experiences versus deficits in normal function.

  • Think: Added pathological experiences versus deficits in normal function.
  • Priority: Positive symptoms (hallucinations, delusions) respond well to antipsychotics; negative symptoms (avolition, flat affect) cause profound long-term disability and respond better to SGAs.
  • Boards are testing: SGAs modulate 5-HT2A and D2 receptors to better address negative symptoms compared to FGAs.
• Common Board Traps and Clinical Safety SignpostsSecond-generation antipsychotics (SGAs) such as risperidone, olanzapine, or quetiapine are first-line pharmacotherapy for acute active-phase hallucinations and delusions due to lower EPS risk compared to first-generation antipsychotics (FGAs).

  • When evaluating a patient with active hallucinations, always assess for command auditory hallucinations instructing self-harm or violence. Violent episodes in untreated schizophrenia are frequently driven by response to active hallucinations or severe persecutory delusions.
  • Second-generation antipsychotics (SGAs) such as risperidone, olanzapine, or quetiapine are first-line pharmacotherapy for acute active-phase hallucinations and delusions due to lower EPS risk compared to first-generation antipsychotics (FGAs).

  Board trap. Diagnosing schizophrenia in an elderly patient presenting with new-onset isolated visual hallucinations. Late-onset primary schizophrenia after age 60 is extremely rare. Always rule out medical causes, drug toxicity, delirium, or visual release phenomena like Charles Bonnet syndr

  Safety. When evaluating a patient with active hallucinations, always assess for command auditory hallucinations instructing self-harm or violence. Violent episodes in untreated schizophrenia are frequently driven by response to active hallucinations or severe persecutory delusions.

• Which of the following statements is false regarding schizophrenia and safety risks?A. A violent episode in schizophrenia can occur in response to a hallucination.

  • A. A violent episode in schizophrenia can occur in response to a hallucination.
  • B. The presence of a major depressive disorder episode increases the risk of a suicide attempt in schizophrenia.
  • C. Suicide is attempted by up to 50% of patients with schizophrenia.
  • D. Patients with schizophrenia who are receiving treatment are more likely to commit homicide than members of the general public.
• Negative symptoms profileSchizophrenia includes five core psychotic domains: delusions, hallucinations, disorganized thinking, grossly disorganized or abnormal motor behavior, and negative symptoms.

  • Schizophrenia includes five core psychotic domains: delusions, hallucinations, disorganized thinking, grossly disorganized or abnormal motor behavior, and negative symptoms.
  • Negative symptoms have a slower onset than positive symptoms, frequently present during the prodromal and residual phases, and are the primary drivers of long-term disability and functional impairment.
  • First-generation antipsychotics (FGAs) treat positive symptoms via dopamine antagonism but do not effectively control negative symptoms.
  • Second-generation antipsychotics (SGAs) provide superior efficacy for negative symptoms due to combined serotonin receptor antagonism and dopamine modulation.
  • Female patients with schizophrenia generally exhibit later onset (ages 25 to 35 compared to ages 10 to 25 in males), better social functioning, and fewer negative symptoms.
  • Non-pharmacological interventions like social skills training, cognitive behavioral therapy for psychosis, and assertive community treatment are essential to address disability driven by negative symptoms.
• Symptom Profile and Clinical FeaturesDiminished emotional expression: Unresponsive facial expression, blunted or flat affect, reduced eye contact, and decreased vocal inflection.

  • Diminished emotional expression: Unresponsive facial expression, blunted or flat affect, reduced eye contact, and decreased vocal inflection.
  • Avolition: Severe reduction in self-initiated, goal-directed activities such as work, school, or personal hygiene.
  • Alogia: Poverty of speech characterized by brief, laconic, or empty responses.
  • Anhedonia: Decreased capacity to experience pleasure from previously enjoyable activities.
  • Asociality: Lack of interest in social interactions and severe social withdrawal.
  • Thought blocking: Abrupt cessation in the train of thought before an idea is completed, leading to silent pauses.
• SignpostsSecond-generation antipsychotics are first-line pharmacotherapy for schizophrenia due to lower risk of EPS, lower risk of tardive dyskinesia, and improved efficacy against negative symptoms.

  • Negative symptoms like severe avolition and asociality often lead to profound self-neglect, poor grooming, or failure to manage co-occurring medical conditions such as type 2 diabetes or cardiovascular disease. Always assess self-care capability and ADL execution.
  • Second-generation antipsychotics are first-line pharmacotherapy for schizophrenia due to lower risk of EPS, lower risk of tardive dyskinesia, and improved efficacy against negative symptoms.

  Board trap. Test items often present a patient who is quiet, withdrawn, and lacking eye contact, tempting test-takers to diagnose primary major depressive disorder. If the stem describes thought blocking, gradual decline in ADLs over six months, or residual phase findings without prominent d

  Safety. Negative symptoms like severe avolition and asociality often lead to profound self-neglect, poor grooming, or failure to manage co-occurring medical conditions such as type 2 diabetes or cardiovascular disease. Always assess self-care capability and ADL execution.

• Positive SymptomsDefinition: Excess or addition of abnormal experiences not present in healthy individuals.

  • Definition: Excess or addition of abnormal experiences not present in healthy individuals.
  • Clinical examples: Delusions, hallucinations, loose associations, tangentiality, and disorganized behavior.
  • Phase of illness: Dominant during the acute active phase.
  • Treatment response: Highly responsive to both first-generation antipsychotics and second-generation antipsychotics.
• Negative SymptomsDefinition: Deficit or absence of normal functions present in healthy individuals.

  • Definition: Deficit or absence of normal functions present in healthy individuals.
  • Clinical examples: Flat affect, avolition, alogia, anhedonia, asociality, and thought blocking.
  • Phase of illness: Dominant during the prodromal and residual phases; primary driver of chronic disability.
  • Treatment response: Poor response to first-generation antipsychotics; better managed with second-generation antipsychotics and social skills training.
• Diagnostic timeline and rulesSchizophrenia requires continuous signs of disturbance for at least 6 months, which must include at least 1 month of active-phase Criterion A symptoms.

  • Schizophrenia requires continuous signs of disturbance for at least 6 months, which must include at least 1 month of active-phase Criterion A symptoms.
  • Active-phase Criterion A requires 2 or more psychotic features (delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, negative symptoms), and at least 1 of those symptoms must be delusions, hallucinations, or disorganized speech.
  • Brief psychotic disorder lasts less than 1 month with a return to full premorbid baseline functioning, whereas schizophreniform disorder lasts at least 1 month but less than 6 months.
  • Schizophreniform disorder does not require social or occupational functional decline, unlike schizophrenia, which requires marked impairment in major life domains.
  • Delusional disorder involves 1 or more delusions lasting at least 1 month without marked functional impairment or prominent hallucinations.
  • Schizoaffective disorder requires a major mood episode concurrent with Criterion A symptoms, plus at least 2 weeks of delusions or hallucinations in the absence of a major mood episode during the lifetime course of the illness.
• Diagnostic Timeline HierarchyBrief psychotic disorder: Symptoms last at least 1 day but less than 1 month, with eventual full return to baseline functioning. Culturally sanctioned responses, such as seeing or hearing a recently deceased loved one during bereavement, are explicitly excluded.

  • Brief psychotic disorder: Symptoms last at least 1 day but less than 1 month, with eventual full return to baseline functioning. Culturally sanctioned responses, such as seeing or hearing a recently deceased loved one during bereavement, are explicitly excluded.
  • Schizophreniform disorder: Symptoms last at least 1 month but less than 6 months. It requires 2 or more Criterion A features, with at least 1 being delusions, hallucinations, or disorganized speech. Social or occupational decline is not required.
  • Delusional disorder: Characterized by 1 or more persistent delusions lasting for 1 month or longer. Aside from the impact of the delusion, daily functioning is not markedly impaired, and behavior is not obviously bizarre.
• Core Psychotic Domains1. Delusions: Fixed false beliefs that persist despite clear conflicting evidence. Common types include persecutory (most common), referential, grandiose, erotomanic, nihilistic, and somatic.

  • 1. Delusions: Fixed false beliefs that persist despite clear conflicting evidence. Common types include persecutory (most common), referential, grandiose, erotomanic, nihilistic, and somatic.
  • 2. Hallucinations: Perception-like experiences occurring without an external stimulus. Auditory hallucinations are most common. Hypnagogic (falling asleep) and hypnopompic (waking up) hallucinations are normal physiological phenomena and not psychotic symptoms.
  • 3. Disorganized speech: Formal thought disorder inferred from speech, such as derailment (loose associations), tangentiality, or word salad.
  • 4. Grossly disorganized or catatonic behavior: Motor abnormalities ranging from childlike silliness to unpredictable agitation or catatonic immobility.
  • 5. Negative symptoms: Deficits in normal functioning, including avolition (lack of goal-directed activity), diminished emotional expression (flat affect), alogia, and asociality. Negative symptoms drive long-term disability and respond poorly to first-generation antipsychotics.
• Etiology and Genetic ProximityMonozygotic twins: 50% concordance risk (and 50% chance of not developing the illness).

  • Monozygotic twins: 50% concordance risk (and 50% chance of not developing the illness).
  • Both parents affected: 40% risk for offspring.
  • One parent affected: 12% risk for offspring.
  • Non-twin sibling affected: 8% risk.
  • General population: 0.7% risk.
  • Environmental and perinatal factors: Winter or spring birth season, maternal influenza, perinatal hypoxia, maternal starvation, and advanced paternal age increase vulnerability.
• Brief Psychotic Disorder vs. Schizophreniform Disorder vs. SchizophreniaThink: Timeline determines the diagnosis.

  • Think: Timeline determines the diagnosis.
  • Brief psychotic disorder: Duration is under 1 month. Full recovery expected.
  • Schizophreniform disorder: Duration is 1 to 6 months. Functions as a provisional diagnosis before 6 months elapse. Social decline is not required.
  • Schizophrenia: Duration is 6 months or greater. Functional decline in major life areas is required.
  • What boards are testing: Recognizing when a question stem specifies symptom duration. If symptoms have lasted 3 months, the correct diagnosis is schizophreniform disorder, not schizophrenia.
• Schizoaffective Disorder vs. Major Depressive Disorder with Psychotic FeaturesThink: Presence of psychosis without mood symptoms.

  • Think: Presence of psychosis without mood symptoms.
  • Schizoaffective disorder: Psychotic symptoms must occur for at least 2 weeks without any major mood symptoms present. Mood symptoms are present for a substantial portion of the total illness.
  • Major depressive disorder with psychotic features: Psychotic symptoms occur exclusively during an active major depressive episode. Once the mood episode resolves, the psychosis completely resolves.
  • What boards are testing: Identifying whether hallucinations or delusions persist when mood is euthymic.
• Primary Psychosis vs. Medical or Substance-Induced PsychosisThink: Gate 1 rules out the body; Gate 2 rules out substances.

  • Think: Gate 1 rules out the body; Gate 2 rules out substances.
  • Medical mimics: CNS tumors, temporal lobe epilepsy, Huntington disease, neurosyphilis, B12 or thiamine deficiency, Cushing syndrome, and Charles Bonnet syndrome (visual hallucinations in visually impaired older adults with intact cognition).
  • Substance-induced psychosis: Onset occurs during or within 1 month of substance intoxication, withdrawal, or medication use (amphetamines, cocaine, corticosteroids, anticholinergics, alcohol/barbiturate withdrawal).
  • What boards are testing: Always rule out physical, endocrine, neurological, or toxic causes before assigning a primary psychiatric diagnosis.
• First-Line InterventionsFirst-line psychosocial interventions: Coordinated specialty care (first-episode psychosis programs), cognitive behavioral therapy for psychosis (CBT-p), assertive community treatment (ACT) teams, social skills training, and family psychoeducation.

  • First-line psychosocial interventions: Coordinated specialty care (first-episode psychosis programs), cognitive behavioral therapy for psychosis (CBT-p), assertive community treatment (ACT) teams, social skills training, and family psychoeducation.
• Board Traps to AvoidPrematurely diagnosing schizophrenia when symptoms have lasted less than 6 months. Always select schizophreniform disorder if the timeline is between 1 and 6 months.

  • Prematurely diagnosing schizophrenia when symptoms have lasted less than 6 months. Always select schizophreniform disorder if the timeline is between 1 and 6 months.
  • Assuming visual hallucinations in an older adult with macular degeneration represent schizophrenia. This is Charles Bonnet syndrome, a visual release phenomenon with intact cognition and preserved insight.
  • Recommending psychodynamic psychotherapy for schizophrenia. Psychodynamic therapy is not evidence-based for schizophrenia and can exacerbate anxiety or regression; CBT, ACT, and social skills training are the evidence-based modalities.
  • Believing treated patients with schizophrenia carry a higher risk of homicide. When medicated and stable, homicide rates match the general population.
  • Overlooking tobacco smoking interactions. Tobacco smoke byproducts induce CYP1A2, lowering blood levels of clozapine and olanzapine. Hospital discharge and smoking resumption can cause a steep drop in drug levels and trigger psychotic relapse.

  Board trap. Prematurely diagnosing schizophrenia when symptoms have lasted less than 6 months. Always select schizophreniform disorder if the timeline is between 1 and 6 months.

• Duration-based differential diagnosesBrief psychotic disorder requires at least 1 core psychotic symptom lasting less than 1 month, with a full return to premorbid functioning.

  • Brief psychotic disorder requires at least 1 core psychotic symptom lasting less than 1 month, with a full return to premorbid functioning.
  • Schizophreniform disorder requires 2 or more characteristic symptoms lasting at least 1 month but less than 6 months, and does not require functional decline.
  • Schizophrenia requires continuous signs of disturbance for at least 6 months, including at least 1 month of active phase symptoms and significant social or occupational dysfunction.
  • Schizophrenia active phase requires at least 2 characteristic symptoms, with at least 1 being delusions, hallucinations, or disorganized speech.
  • Delusional disorder requires 1 or more delusions for at least 1 month without marked functional impairment outside the delusion.
  • Schizoaffective disorder requires a major mood episode concurrent with active psychotic symptoms, plus at least 2 weeks of delusions or hallucinations without prominent mood symptoms.

  Safety. Always rule out substance-induced psychotic disorder and medical causes such as delirium, neurodegenerative conditions, or metabolic abnormalities before diagnosing a primary psychotic disorder.

• Delusional Disorder vs. Primary Psychotic DisordersTimeline and features: Delusional disorder involves 1 or more delusions lasting for at least 1 month.

  • Timeline and features: Delusional disorder involves 1 or more delusions lasting for at least 1 month.
  • Functioning: Hallucinations are absent or non-prominent, and functioning is not markedly impaired outside the specific impact of the delusion.
  • Subtypes include persecutory, jealous, grandiose, erotomanic, somatic, and bizarre content.
  • First-line management: Second generation antipsychotics such as quetiapine or risperidone can reduce delusional intensity and allow patients to maintain daily employment and social roles.
• Schizoaffective Disorder vs. Mood Disorder with Psychotic FeaturesPsychotic timing difference: In schizoaffective disorder, delusions or hallucinations must be present for at least 2 weeks in the absence of a major mood episode during the lifetime course of the illness.

  • Psychotic timing difference: In schizoaffective disorder, delusions or hallucinations must be present for at least 2 weeks in the absence of a major mood episode during the lifetime course of the illness.
  • In major depressive disorder with psychotic features or bipolar mania with psychosis, psychotic symptoms occur exclusively during an active mood episode.
  • Misdiagnosing schizophrenia in a patient who has concurrent manic or depressive episodes without verifying whether psychotic symptoms occur independently for at least 2 weeks without mood symptoms.

  Board trap. Misdiagnosing schizophrenia in a patient who has concurrent manic or depressive episodes without verifying whether psychotic symptoms occur independently for at least 2 weeks without mood symptoms.

• FGA vs SGA selectionMechanism of action differences: First-generation antipsychotics (FGAs) act via potent D2 dopamine receptor antagonism. SGAs combine D2 dopamine antagonism with 5-HT2A serotonin antagonism or partial agonism, which mitigates EPS and addresses negative symptoms.

  • Mechanism of action differences: First-generation antipsychotics (FGAs) act via potent D2 dopamine receptor antagonism. SGAs combine D2 dopamine antagonism with 5-HT2A serotonin antagonism or partial agonism, which mitigates EPS and addresses negative symptoms.
  • Clozapine monitoring timeline: ANC monitoring is required weekly for the first 6 months, every 2 weeks for months 6 through 12, and monthly thereafter. Small bowel obstruction from severe constipation is a major physical safety risk requiring a prophylactic bowel regimen.
  • Tobacco smoke induction: Tobacco smoke byproducts induce the CYP1A2 isoenzyme, significantly decreasing blood levels of clozapine and olanzapine. Quitting smoking leads to rising drug levels and potential toxicity.
  • NMS clinical presentation: Neuroleptic Malignant Syndrome (NMS) presents with muscle rigidity, hyperthermia, altered mental status, and autonomic instability. Serum creatine kinase (CK) elevates above 1,000 IU/L up to 100,000 IU/L due to severe rhabdomyolysis.
  • Metabolic monitoring parameters: SGAs require baseline BMI, blood pressure, fasting blood glucose or HbA1c, and lipid panel, with follow-up metabolic screening every 3 to 12 months.
• First-Line Antipsychotic Selection and Receptor DynamicsDo not confuse local clinic prescribing habits with national examination standards. On board exams, FGAs are never first-line choices unless a patient has a documented history of excellent response and minimal side effects on an FGA in the past.

  • Do not confuse local clinic prescribing habits with national examination standards. On board exams, FGAs are never first-line choices unless a patient has a documented history of excellent response and minimal side effects on an FGA in the past.

  Board trap. Do not confuse local clinic prescribing habits with national examination standards. On board exams, FGAs are never first-line choices unless a patient has a documented history of excellent response and minimal side effects on an FGA in the past.

  Safety. SGAs carry a significant risk for metabolic syndrome. Olanzapine and clozapine produce the highest risk of weight gain, dyslipidemia, and new-onset diabetes. Quetiapine produces marked sedation and weight gain. Ziprasidone is metabolic-neutral but carries the highest risk of QTc

• Treatment-Resistant Psychosis and Clozapine ManagementClozapine is the most effective antipsychotic for severe, refractory schizophrenia.

  • Clozapine is the most effective antipsychotic for severe, refractory schizophrenia.
  • It is indicated after a patient fails at least two adequate trials of other antipsychotics, or when severe persistent suicidality or uncontrollable aggression is present.
  • **Safety alert**: Clozapine carries a 1% to 2% risk of life-threatening agranulocytosis.
  • Baseline ANC must be checked prior to initiation and must be at least 1,500/mm3 for the general population or at least 1,000/mm3 for individuals with documented benign ethnic neutropenia.

  Board trap. Tobacco smoking induces the CYP1A2 enzyme through aromatic hydrocarbons in smoke, not through nicotine itself. Because clozapine and olanzapine are CYP1A2 substrates, smoking lowers their serum concentrations. If a patient on clozapine is hospitalized and forced to stop smoking,

  Safety. Clozapine carries a 1% to 2% risk of life-threatening agranulocytosis. Baseline ANC must be checked prior to initiation and must be at least 1,500/mm3 for the general population or at least 1,000/mm3 for individuals with documented benign ethnic neutropenia. The monitoring schedu

• Extrapyramidal side effects arise from D2 blockade within the nigrostriatal pathwayAkathisia: Subjective motor restlessness, pacing, and an internal feeling of wanting to jump out of one's skin. Treat by lowering the antipsychotic dose, switching to an agent with lower EPS risk, or adding a beta-blocker such as propranolol.

  • Akathisia: Subjective motor restlessness, pacing, and an internal feeling of wanting to jump out of one's skin. Treat by lowering the antipsychotic dose, switching to an agent with lower EPS risk, or adding a beta-blocker such as propranolol.
• Neuroleptic Malignant SyndromeSevere muscle rigidity ("lead-pipe" rigidity)

  • Severe muscle rigidity ("lead-pipe" rigidity)
  • Hyperthermia (fever often exceeding 102 degrees Fahrenheit)
  • Altered level of consciousness (confusion, delirium, coma)
  • Autonomic instability (tachycardia, labile blood pressure, profuse diaphoresis)

  Safety. Neuroleptic Malignant Syndrome is a life-threatening medical emergency with a 10% to 20% mortality rate. It can occur within 45 minutes to 65 days after starting or increasing an antipsychotic, or when rapidly switching agents. Risk factors include rapid dose escalation, parenter

• Laboratory and QTc Monitoring GuidelinesBaseline assessment: BMI, blood pressure, fasting plasma glucose or HbA1c, lipid panel, CBC, renal function, liver function tests, and baseline EKG.

  • Baseline assessment: BMI, blood pressure, fasting plasma glucose or HbA1c, lipid panel, CBC, renal function, liver function tests, and baseline EKG.
  • Ongoing metabolic monitoring: Re-check weight at every visit; monitor fasting glucose and lipids at 3 months, then annually.
  • QTc Prolongation: Normal QTc is less than 450 ms in men and less than 470 ms in women. A QTc interval exceeding 500 ms or an increase of 60 ms or more from baseline warrants immediate drug discontinuation and cardiology consultation.
• Metabolic monitoring protocolBaseline metabolic screening before starting any second-generation antipsychotic requires personal and family cardiovascular history, height, weight, BMI, waist circumference, blood pressure, fasting plasma glucose or HbA1c, and a fasting lipid profile.

  • Baseline metabolic screening before starting any second-generation antipsychotic requires personal and family cardiovascular history, height, weight, BMI, waist circumference, blood pressure, fasting plasma glucose or HbA1c, and a fasting lipid profile.
  • Weight and BMI must be evaluated monthly for the first 3 months of treatment and then quarterly every 3 months thereafter.
  • Blood pressure, fasting plasma glucose or HbA1c, and fasting lipid profiles must be rechecked at 3 months after starting therapy and then monitored at least annually.
  • clozapine and olanzapine carry the highest risk for extreme weight gain, severe hypertriglyceridemia, insulin resistance, and new-onset diabetes mellitus.
  • quetiapine, risperidone, and paliperidone demonstrate moderate metabolic risk and require strict routine laboratory surveillance.
  • aripiprazole, ziprasidone, lurasidone, cariprazine, and lumateperone are metabolic-neutral second-generation antipsychotics that present low risk for weight gain or glucose elevation.
• High-Yield Concept Map: Metabolic Monitoring ProtocolWhat it is: A standardized clinical screening and laboratory surveillance schedule designed to detect and manage cardiovascular and endocrine complications induced by second-generation antipsychotics.

  • What it is: A standardized clinical screening and laboratory surveillance schedule designed to detect and manage cardiovascular and endocrine complications induced by second-generation antipsychotics.
  • Why boards care: Cardiovascular disease driven by metabolic syndrome is a leading cause of premature mortality in patients with schizophrenia, shortening life expectancy by up to 20 to 25 years.
  • Baseline: Obtain height, weight, BMI, waist circumference, blood pressure, fasting plasma glucose or HbA1c, and fasting lipid panel.
  • 1 month to 3 months: Measure weight and BMI monthly for the first 3 months.
  • 3 months: Recheck blood pressure, fasting plasma glucose, and fasting lipid panel.
  • Quarterly: Re-evaluate weight and BMI every 3 months.

  Safety. Second-generation antipsychotics can trigger rapid-onset diabetic ketoacidosis (DKA) or severe hyperglycemic hyperosmolar state, even in patients without a prior diagnosis of diabetes.

• Clinical Signposts and Strategic Exam RulesOrder baseline fasting plasma glucose, fasting lipid panel, and BMI prior to initiating any second-generation antipsychotic.

  • Order baseline fasting plasma glucose, fasting lipid panel, and BMI prior to initiating any second-generation antipsychotic.
  • clozapine and olanzapine carry black box warnings and high clinical alerts for severe metabolic disruption, requiring vigilant tracking of fasting glucose and lipid parameters.
  • Assuming normal baseline laboratory values eliminate the need for follow-up testing. The exam tests whether you recheck fasting glucose and lipid profiles at the 3-month mark regardless of normal baseline results.

  Board trap. Assuming normal baseline laboratory values eliminate the need for follow-up testing. The exam tests whether you recheck fasting glucose and lipid profiles at the 3-month mark regardless of normal baseline results.

  Safety. clozapine and olanzapine carry black box warnings and high clinical alerts for severe metabolic disruption, requiring vigilant tracking of fasting glucose and lipid parameters.

• Comparative Metabolic Risk Tiers Among Second-Generation AntipsychoticsHigh metabolic risk: clozapine and olanzapine cause the greatest weight gain, profound hypertriglyceridemia, and severe impairment of glucose tolerance due to strong H1 histamine and 5-HT2C serotonin receptor antagonism.

  • High metabolic risk: clozapine and olanzapine cause the greatest weight gain, profound hypertriglyceridemia, and severe impairment of glucose tolerance due to strong H1 histamine and 5-HT2C serotonin receptor antagonism.
  • Moderate metabolic risk: quetiapine, risperidone, and paliperidone produce moderate weight gain and intermediate elevations in glucose and lipid levels.
  • Low metabolic risk: aripiprazole, ziprasidone, lurasidone, cariprazine, and lumateperone are metabolic-neutral agents that produce minimal weight change and negligible metabolic disruption, making them preferred choices for patients with pre-existing obesity or diabetes.
• Active Recall CheckpointsWhat six specific laboratory and physical parameters must be documented at baseline before starting an SGA?

  • What six specific laboratory and physical parameters must be documented at baseline before starting an SGA?
  • How frequently must BMI and weight be measured during the first 3 months of SGA therapy?
  • At what specific post-initiation timeframe must fasting plasma glucose and lipid panels be re-evaluated?
  • Which two second-generation antipsychotics carry the highest risk for severe weight gain, dyslipidemia, and new-onset diabetes mellitus?
  • What percentage of body weight gain from baseline is considered a critical threshold for clinical intervention?
• EPS and NMS managementNeuroleptic malignant syndrome is a life-threatening emergency with a mortality rate of 10% to 20%, characterized by hyperthermia, muscle rigidity, autonomic instability, altered mental status, and a serum creatine kinase level exceeding 1000 IU/L up to 100000 IU/L.

  • Neuroleptic malignant syndrome is a life-threatening emergency with a mortality rate of 10% to 20%, characterized by hyperthermia, muscle rigidity, autonomic instability, altered mental status, and a serum creatine kinase level exceeding 1000 IU/L up to 100000 IU/L.
  • Acute dystonia presents as sudden muscle spasms like torticollis within hours to days of starting antipsychotics, requiring IM or IV benztropine or diphenhydramine for severe episodes.
  • Akathisia presents as motor restlessness and a subjective urge to move; propranolol is the First-line agent.
  • Parkinsonism features bradykinesia, rigidity, and shuffling gait; it is managed by lowering the dose or adding benztropine or amantadine.
  • Clozapine and quetiapine carry the lowest risk of tardive dyskinesia, making them preferred SGAs when motor complications arise.
• Assessment and Risk TimelinesEvaluate patients for extrapyramidal symptoms weekly until the medication dose has been stable for at least 2 weeks.

  • Evaluate patients for extrapyramidal symptoms weekly until the medication dose has been stable for at least 2 weeks.
  • Early extrapyramidal symptoms serve as critical warning signs for the future development of tardive dyskinesia.
• Extrapyramidal Symptom Types and Clinical FeaturesDystonia: Acute, rapid onset of painful muscle contractions, such as torticollis or oculogyric crisis.

  • Dystonia: Acute, rapid onset of painful muscle contractions, such as torticollis or oculogyric crisis.
  • Akathisia: Subjective feeling of internal restlessness or feeling like wanting to jump out of one's skin, accompanied by pacing or foot tapping.
  • Parkinsonism: Stiff, rigid muscles, bradykinesia, shuffling gait, masked facies, resting tremor, and cogwheel rigidity.
• Treatment Strategies for EPSFirst-line for akathisia: Centrally acting beta blockers, specifically propranolol.

  • First-line for akathisia: Centrally acting beta blockers, specifically propranolol.
  • First-line for parkinsonism: Anticholinergic medications such as benztropine or dopamine agonists like amantadine.
  • Treatment for dystonia: Mild symptoms respond to oral benztropine. Severely disturbing acute dystonia requires IM or IV benztropine or diphenhydramine.
  • Prophylactic anticholinergic use is generally not recommended, with one major exception: initiating parenteral haloperidol for acute agitation, particularly in antipsychotic naive patients.

  Board trap. Keeping patients on long term anticholinergics like benztropine can cause severe anticholinergic toxicity and cognitive decline. Anticholinergic drugs should be maintained at the lowest effective dose for the shortest necessary duration and reassessed for discontinuation after we

  Safety. Prophylactic anticholinergic use is generally not recommended, with one major exception: initiating parenteral haloperidol for acute agitation, particularly in antipsychotic naive patients.

• Clinical Presentation and TimingInvoluntary, repetitive muscle movements including facial grimacing, lip smacking, tongue protrusion, rapid eye blinking, and choreiform limb movements.

  • Involuntary, repetitive muscle movements including facial grimacing, lip smacking, tongue protrusion, rapid eye blinking, and choreiform limb movements.
  • Onset occurs during antipsychotic therapy, within 4 weeks of discontinuing an oral antipsychotic, or within 8 weeks of discontinuing a depot long-acting injectable.
• Prevention, Screening, and InterventionScreen all patients receiving antipsychotics using the AIMS (Abnormal Involuntary Movement Scale) tool at baseline and periodically.

  • Screen all patients receiving antipsychotics using the AIMS (Abnormal Involuntary Movement Scale) tool at baseline and periodically.
  • First-line intervention for early detection: Reduce the dose or discontinue the offending agent, or switch from an FGA to an SGA with low EPS liability, specifically clozapine or quetiapine.
  • Treatment for moderate to severe or disabling tardive dyskinesia: VMAT2 inhibitors, such as valbenazine or deutetrabenazine. Secondary options include benzodiazepines or botulinum toxin injections.
• Clinical Presentation and Lab FindingsNeuroleptic malignant syndrome is a medical emergency with a 10% to 20% mortality rate.

  • Neuroleptic malignant syndrome is a medical emergency with a 10% to 20% mortality rate.
  • Clinical presentation is remembered as hot, stiff, and out of it: severe hyperthermia, extreme generalized muscle rigidity, altered level of consciousness, and autonomic dysfunction (tachycardia, labile blood pressure, diaphoresis).

  Safety. Neuroleptic malignant syndrome is a medical emergency with a 10% to 20% mortality rate.

• Timing, Triggering Agents, and Risk FactorsCan develop as early as 45 minutes or as late as 65 days after antipsychotic initiation or dose adjustment.

  • Can develop as early as 45 minutes or as late as 65 days after antipsychotic initiation or dose adjustment.
  • Contributing risk factors: Rapid dose escalation, parenteral administration, switching antipsychotics, and concurrent use of lithium, anticholinergic, or serotonergic agents.

  Board trap. Assuming neuroleptic malignant syndrome only occurs with high-potency FGAs like haloperidol. While the incidence is highest with FGAs (up to 3%), it can also occur with SGAs, antiemetic dopamine antagonists (such as metoclopramide, promethazine, prochlorperazine, droperidol), or

• Emergency Management ProtocolFirst-line action: Immediately discontinue the offending antipsychotic and all potential contributing psychotropic agents.

  • First-line action: Immediately discontinue the offending antipsychotic and all potential contributing psychotropic agents.
  • Medical stabilization: Transfer the patient immediately to an intensive care or tertiary care facility for aggressive supportive care, including IV hydration to preserve renal function and active cooling measures.
  • Pharmacologic treatment in severe cases: Administer the direct acting muscle relaxant dantrolene or the dopamine agonist bromocriptine.
• Keyed Letter: DChoice A is incorrect because serum transaminases (ALT/AST) evaluate hepatic function, which is unrelated to identifying or scoring movement disorders.

  • Choice A is incorrect because serum transaminases (ALT/AST) evaluate hepatic function, which is unrelated to identifying or scoring movement disorders.
  • Choice B is incorrect because serum creatinine evaluates renal clearance, which does not assist in evaluating motor side effects.
  • Choice C is incorrect because the PHQ-9 measures depressive symptoms, not extrapyramidal or dyskinetic movement disorders.
• Keyed Letter: CChoice A is incorrect because an elevated HbA1c reflects chronic glycemic control or metabolic syndrome, not acute rhabdomyolysis from neuroleptic malignant syndrome.

  • Choice A is incorrect because an elevated HbA1c reflects chronic glycemic control or metabolic syndrome, not acute rhabdomyolysis from neuroleptic malignant syndrome.
  • Choice B is incorrect because elevated platelet count (thrombocytosis) is an acute phase reactant or hematologic finding, not the defining diagnostic lab for neuroleptic malignant syndrome.
  • Choice D is incorrect because an elevated liver enzyme ratio reflects hepatotoxicity or alcohol-induced liver disease rather than acute muscle destruction.
• Treatment resistance definitionTreatment resistance definition: Treatment-resistant schizophrenia is defined as little or no symptomatic response following at least two adequate trials of different antipsychotics at therapeutic dose ranges for at least 6 weeks each.

  • Treatment resistance definition: Treatment-resistant schizophrenia is defined as little or no symptomatic response following at least two adequate trials of different antipsychotics at therapeutic dose ranges for at least 6 weeks each.
  • Clozapine indication: Clozapine is the gold-standard third-line agent for treatment-resistant schizophrenia, persistent suicide attempt risk, or chronic aggressive behavior.
  • Absolute Neutrophil Count (ANC) criteria: Baseline ANC must be at least 1500 / mm3 (or at least 1000 / mm3 for benign ethnic neutropenia) before starting clozapine. Interrupt treatment if ANC drops below 1000 / mm3.
  • Clozapine monitoring schedule: Monitor ANC weekly for the first 6 months, biweekly for months 6 through 12, and monthly thereafter for the duration of therapy.
  • Smoking interaction via CYP1A2: Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2, accelerating clozapine and olanzapine metabolism and lowering blood levels. Smoking cessation increases drug levels, raising toxicity risk.
  • Long-acting injectables (LAIs): LAIs are the primary strategy for nonadherence. Options include paliperidone palmitate given monthly, every 3 months, or every 6 months, as well as haloperidol decanoate and fluphenazine decanoate.
• Treatment Resistance Definition and Clinical RulesTreatment-resistant schizophrenia occurs when a patient fails to show adequate symptomatic improvement after two or more trials of different antipsychotics.

  • Treatment-resistant schizophrenia occurs when a patient fails to show adequate symptomatic improvement after two or more trials of different antipsychotics.
  • Each trial must be administered at a therapeutic dose range for a minimum duration of 6 weeks.
  • Before declaring true treatment resistance, the clinician must confirm medication adherence, rule out active substance use disorder, and exclude underlying medical causes or drug interactions.
  • **Board trap**: Assuming a patient is treatment-resistant when the true issue is covert nonadherence.

  Board trap. Assuming a patient is treatment-resistant when the true issue is covert nonadherence. Up to 20% of inpatient and 50% of outpatient individuals fail to take oral psychotropics as prescribed. Always evaluate adherence or switch to a long-acting injectable before labeling an illness

• Clozapine Protocols and Safety RulesConfusing total white blood cell (WBC) count with ANC. National guidelines mandate monitoring ANC exclusively, as ANC isolates mature fighting neutrophils from total leukocyte counts.

  • Confusing total white blood cell (WBC) count with ANC. National guidelines mandate monitoring ANC exclusively, as ANC isolates mature fighting neutrophils from total leukocyte counts.
  • Gastrointestinal hypomotility: Severe constipation can progress to paralytic ileus or small bowel obstruction. Every patient on clozapine should be placed on a prophylactic bowel regimen such as docusate or polyethylene glycol.
  • Metabolic and neurological risks: Clozapine carries high risks for weight gain, dyslipidemia, new-onset diabetes, dose-dependent seizures, myocarditis, orthostatic hypotension, and severe sialorrhea (drooling).

  Board trap. Confusing total white blood cell (WBC) count with ANC. National guidelines mandate monitoring ANC exclusively, as ANC isolates mature fighting neutrophils from total leukocyte counts.

  Safety. Clozapine carries a risk of life-threatening agranulocytosis in 1% to 2% of patients. Absolute Neutrophil Count (ANC) monitoring is mandatory. Baseline ANC must be at least 1500 / mm3 in the general population or at least 1000 / mm3 in individuals with documented benign ethnic ne

• Long-Acting Injectables (LAIs)First-generation LAIs: Haloperidol decanoate and fluphenazine decanoate are administered intramuscularly every 2 to 4 weeks. They carry higher risks for EPS and tardive dyskinesia.

  • First-generation LAIs: Haloperidol decanoate and fluphenazine decanoate are administered intramuscularly every 2 to 4 weeks. They carry higher risks for EPS and tardive dyskinesia.
  • Second-generation LAIs: Paliperidone palmitate offers flexible dosing intervals, including monthly formulations, a 3-month formulation, and a 6-month formulation. Risperidone LAI and aripiprazole LAI are also widely utilized options.
  • First-line strategy for nonadherent patients experiencing recurrent relapses is transitioning from oral SGAs to an SGA LAI formulation once oral tolerability is established.
• Which of the following statements is false regarding schizophrenia?A. A violent episode can be in response to a hallucination.

  • A. A violent episode can be in response to a hallucination.
  • B. The presence of a major depressive disorder episode can increase the risk of a suicide attempt.
  • C. Suicide is attempted in up to 50% of patients with schizophrenia.
  • D. Patients with schizophrenia are more likely to commit a homicide than a member of the general public.
• Clozapine ANC monitoring rulesClozapine is indicated for treatment-resistant schizophrenia after failure of at least two adequate trials of different antipsychotics, or for persistent suicidal behavior or severe aggression.

  • Clozapine is indicated for treatment-resistant schizophrenia after failure of at least two adequate trials of different antipsychotics, or for persistent suicidal behavior or severe aggression.
  • Baseline Absolute Neutrophil Count (ANC) must be ≥1500/mm³ in the general population, or ≥1000/mm³ for individuals with documented Benign Ethnic Neutropenia (BEN), before initiating Clozapine.
  • ANC monitoring for Clozapine requires weekly blood draws for the first 6 months, biweekly draws for months 6 through 12, and monthly draws thereafter if ANC remains ≥1500/mm³.
  • Interrupt Clozapine therapy immediately if ANC drops below 1000/mm³ due to the risk of life-threatening agranulocytosis, which occurs in 1% to 2% of patients.
  • Tobacco smoke hydrocarbons induce CYP1A2, decreasing serum levels of Clozapine and Olanzapine. Stopping smoking increases drug levels, whereas resuming smoking decreases levels and risks psychotic relapse.
  • Clozapine carries a severe risk of gastrointestinal hypomotility and fatal small bowel obstruction, requiring proactive daily bowel management.
• Clinical Masterclass: Clozapine, LAIs, and Treatment-Resistance RulesFirst-line psychopharmacology for schizophrenia consists of second-generation antipsychotics due to equivalent efficacy for positive symptoms and a significantly lower risk of extrapyramidal symptoms and tardive dyskinesia compared to first-generation agents.

  • First-line psychopharmacology for schizophrenia consists of second-generation antipsychotics due to equivalent efficacy for positive symptoms and a significantly lower risk of extrapyramidal symptoms and tardive dyskinesia compared to first-generation agents.
• Clozapine Indications and Treatment ResistanceAgranulocytosis occurs in 1% to 2% of patients treated with Clozapine. This is a sudden, potentially fatal drop in neutrophils that severely compromises immune defense.

  • Agranulocytosis occurs in 1% to 2% of patients treated with Clozapine. This is a sudden, potentially fatal drop in neutrophils that severely compromises immune defense.

  Safety. Agranulocytosis occurs in 1% to 2% of patients treated with Clozapine. This is a sudden, potentially fatal drop in neutrophils that severely compromises immune defense.

• CYP1A2 Drug Interactions and Tobacco SmokeActive tobacco smokers require higher doses of Clozapine to maintain therapeutic serum levels.

  • Active tobacco smokers require higher doses of Clozapine to maintain therapeutic serum levels.
  • When a patient is admitted to a smoke-free inpatient unit and stops smoking, CYP1A2 induction disappears, causing Clozapine serum levels to double and risking severe toxicity and sedation.
  • When a patient is discharged and resumes smoking, CYP1A2 is re-induced, causing Clozapine levels to drop significantly and risking psychotic relapse.

  Safety. Clozapine causes severe anticholinergic gastrointestinal hypomotility, which can lead to severe constipation, fecal impaction, toxic megacolon, and fatal small bowel obstruction. Prescribers must monitor bowel movements regularly and maintain patients on a daily prophylactic bowe

• Long-Acting Injectable Antipsychotics (LAIs)LAIs are indicated when patients exhibit partial or full nonadherence to daily oral antipsychotics.

  • LAIs are indicated when patients exhibit partial or full nonadherence to daily oral antipsychotics.
  • Paliperidone is available as a 1-month injection (Invega Sustenna), a 3-month injection (Invega Trinza), and a 6-month injection (Hafyera).
  • Additional LAIs include Risperidone, Haloperidol decanoate, and Fluphenazine decanoate.
  • LAIs maintain consistent therapeutic plasma levels, eliminate daily pill burdens, and substantially reduce relapse and rehospitalization rates.
• Clozapine safety and side effectsFirst-line second-generation antipsychotics (SGAs) are preferred for schizophrenia, but clozapine is the gold-standard third-line agent for treatment-resistant schizophrenia, persistent suicide risk, or refractory aggression.

  • First-line second-generation antipsychotics (SGAs) are preferred for schizophrenia, but clozapine is the gold-standard third-line agent for treatment-resistant schizophrenia, persistent suicide risk, or refractory aggression.
  • Absolute Neutrophil Count (ANC) must be greater than or equal to 1,500/mm³ before initiating clozapine therapy.
  • ANC Monitoring Schedule: Baseline ANC, followed by weekly ANC draws for the first 6 months, every 2 weeks for months 6 to 12, and monthly thereafter if ANC remains at or above 1,500/mm³.
  • Interrupt and hold clozapine immediately if the ANC drops below 1,000/mm³ to prevent life-threatening agranulocytosis.
  • Myocarditis risk peaks during the first 6 weeks of clozapine therapy; monitor CRP, troponins, and cardiac symptoms closely if chest pain or shortness of breath occurs.
  • Gastrointestinal hypomotility and paralytic ileus cause severe bowel obstruction; initiate a proactive bowel regimen such as Miralax at treatment onset.
• Indications and Line of TherapySecond-generation antipsychotics like risperidone, olanzapine, or aripiprazole are first-line for schizophrenia due to lower extrapyramidal side effect (EPS) risk.

  • Second-generation antipsychotics like risperidone, olanzapine, or aripiprazole are first-line for schizophrenia due to lower extrapyramidal side effect (EPS) risk.
  • Clozapine indication: Indicated after failure of at least two adequate trials of different antipsychotics. It is uniquely indicated for reducing suicide risk in schizophrenia and controlling refractory violent or aggressive behavior.
  • Do not start clozapine as first-line therapy for uncomplicated acute psychosis. Boards test clozapine as a third-line intervention reserved for treatment resistance or severe suicidality.

  Board trap. Do not start clozapine as first-line therapy for uncomplicated acute psychosis. Boards test clozapine as a third-line intervention reserved for treatment resistance or severe suicidality.

• Hematologic Safety and ANC RulesAgranulocytosis occurs in 1% to 2% of patients taking clozapine and can lead to fatal sepsis.

  • Agranulocytosis occurs in 1% to 2% of patients taking clozapine and can lead to fatal sepsis.
  • ANC threshold: Baseline ANC must be at least 1,500/mm³ (or 1,000/mm³ for confirmed benign ethnic neutropenia).
  • Monitoring frequency:
  • 1. Months 1 to 6: Draw ANC weekly.
  • 2. Months 7 to 12: Draw ANC every 2 weeks.
  • 3. Month 12 onward: Draw ANC monthly for the duration of treatment.

  Safety. Agranulocytosis occurs in 1% to 2% of patients taking clozapine and can lead to fatal sepsis.

• Cardiovascular and Neurologic Red FlagsClozapine carries a black box warning for fatal myocarditis and cardiomyopathy. The peak window for myocarditis is the first 6 weeks. Any fever, chest pain, dyspnea, tachycardia, or palpitations during initial titration requires immediate ECG, troponin, and CRP labs.

  • Clozapine carries a black box warning for fatal myocarditis and cardiomyopathy. The peak window for myocarditis is the first 6 weeks. Any fever, chest pain, dyspnea, tachycardia, or palpitations during initial titration requires immediate ECG, troponin, and CRP labs.
  • Seizure risk: Clozapine lowers the seizure threshold in a dose-dependent fashion. At doses exceeding 300 to 600 mg daily, seizure risk rises sharply.
  • Orthostatic hypotension: Severe orthostasis, bradycardia, and syncope can occur during rapid titration. Slow, gradual dose escalation is mandatory.

  Safety. Clozapine carries a black box warning for fatal myocarditis and cardiomyopathy. The peak window for myocarditis is the first 6 weeks. Any fever, chest pain, dyspnea, tachycardia, or palpitations during initial titration requires immediate ECG, troponin, and CRP labs.

• Gastrointestinal and Metabolic ComplicationsClozapine-induced gastrointestinal hypomotility can progress to paralytic ileus, bowel ischemia, small bowel obstruction, and death. Constipation must be managed proactively with daily stool softeners or osmotic laxatives like Miralax.

  • Clozapine-induced gastrointestinal hypomotility can progress to paralytic ileus, bowel ischemia, small bowel obstruction, and death. Constipation must be managed proactively with daily stool softeners or osmotic laxatives like Miralax.
  • Sialorrhea: Nocturnal drooling is extremely common due to complex muscarinic actions. Treat with sublingual ipratropium spray or atropine 1% ophthalmic drops administered orally under the tongue.
  • Metabolic syndrome: Clozapine and olanzapine carry the highest risk for marked weight gain, severe dyslipidemia, and new-onset type 2 diabetes. Baseline and routine monitoring of BMI, fasting plasma glucose, and lipid panels is required.

  Safety. Clozapine-induced gastrointestinal hypomotility can progress to paralytic ileus, bowel ischemia, small bowel obstruction, and death. Constipation must be managed proactively with daily stool softeners or osmotic laxatives like Miralax.

• Drug Interactions and CYP1A2 Smoking EffectsTobacco smoke contains polycyclic aromatic hydrocarbons that act as potent inducers of the CYP1A2 enzyme, which metabolizes clozapine.

  • Tobacco smoke contains polycyclic aromatic hydrocarbons that act as potent inducers of the CYP1A2 enzyme, which metabolizes clozapine.
  • When a patient who smokes heavily is admitted to a smoke-free inpatient unit, CYP1A2 induction stops. Clozapine levels rise, risking toxicity, extreme sedation, and seizures.
  • When discharged, if the patient resumes heavy smoking, CYP1A2 is induced again. Clozapine levels fall rapidly, risking loss of efficacy and psychotic relapse.

  Board trap. Tobacco smoke contains polycyclic aromatic hydrocarbons that act as potent inducers of the CYP1A2 enzyme, which metabolizes clozapine.

• Long-Acting Injectables (LAI)Primary indication: Long-acting injectables (LAIs) are indicated for patients with schizophrenia who exhibit partial or full medication non-adherence, recurrent relapses, or personal preference for non-daily dosing.

  • Primary indication: Long-acting injectables (LAIs) are indicated for patients with schizophrenia who exhibit partial or full medication non-adherence, recurrent relapses, or personal preference for non-daily dosing.
  • First-generation LAIs: Include haloperidol decanoate and fluphenazine decanoate, which carry a higher risk of extrapyramidal symptoms (EPS) and tardive dyskinesia.
  • Second-generation LAIs: Include risperidone (Consta), paliperidone palmitate (Invega Sustenna, Invega Trinza, Invega Hafyera), and aripiprazole (Abilify Maintena, Aristada).
  • Extended dosing intervals: Invega Sustenna is administered monthly, Invega Trinza is administered every 3 months after establishing monthly stability, and Invega Hafyera is administered every 6 months.
  • Relapse prevention: Maintenance antipsychotic therapy with LAIs reduces the annual relapse rate to under 30 percent, preventing progressive cognitive and functional deterioration.
  • Tardive dyskinesia timeline: Withdrawal emergence or onset of tardive dyskinesia occurs within 4 weeks of stopping oral antipsychotics, but can take up to 8 weeks following cessation of a depot LAI.
• High-Yield Concept Map: Long-Acting Injectables (LAI)What it is: Depot formulations of first- and second-generation antipsychotics administered via deep intramuscular injection to maintain sustained therapeutic plasma drug levels.

  • What it is: Depot formulations of first- and second-generation antipsychotics administered via deep intramuscular injection to maintain sustained therapeutic plasma drug levels.
  • Why boards care: Non-adherence is the primary driver of psychotic relapse, emergency department visits, and rehospitalization in schizophrenia. LAIs eliminate covert non-adherence.
  • Up to 20 percent of patients are non-adherent even in structured inpatient settings, and over 50 percent relapse within two years of a first episode. Each relapse causes permanent functional decline.
  • Typical board clue: A patient with recurrent hospitalizations who promises they are taking their daily oral medication, or a patient who stops oral meds due to forgetfulness or lack of insight.
  • First-line approach: Second-generation LAIs are preferred over first-generation LAIs due to lower EPS and tardive dyskinesia risk.
  • When the answer changes: If the patient has failed two or more adequate trials of different antipsychotics despite confirmed adherence, switch to clozapine rather than another LAI.

  Safety. Always confirm oral tolerability before giving the first injection to prevent prolonged adverse reactions. Tardive dyskinesia signs can take up to 8 weeks to manifest after discontinuing a depot LAI.

• Signpost RulesSecond-generation antipsychotics (SGAs) are first-line agents for schizophrenia. When non-adherence threatens stability or causes repeated relapse, converting to a second-generation LAI is the first-line secondary prevention strategy.

  • Second-generation antipsychotics (SGAs) are first-line agents for schizophrenia. When non-adherence threatens stability or causes repeated relapse, converting to a second-generation LAI is the first-line secondary prevention strategy.
  • Tardive dyskinesia monitoring with the AIMS scale must occur at baseline and every 3 to 6 months. Remember that depot formulations clear slowly, so adverse effects or tardive dyskinesia emergence may persist or delay onset up to 8 weeks after the last injection.

  Board trap. Test writers like to present a patient who is relapsing due to medication non-adherence and offer clozapine as a choice. Clozapine is reserved for true treatment-resistant schizophrenia (failure of two or more adequate trials) or severe persistent suicide/violence risk. It is not

  Safety. Tardive dyskinesia monitoring with the AIMS scale must occur at baseline and every 3 to 6 months. Remember that depot formulations clear slowly, so adverse effects or tardive dyskinesia emergence may persist or delay onset up to 8 weeks after the last injection.

• Dosing Intervals and FormulationsInvega Sustenna is the 1-month monthly formulation.

  • Invega Sustenna is the 1-month monthly formulation.
  • Invega Trinza is the 3-month formulation, used only after a patient is established on Invega Sustenna for at least 4 months.
  • Invega Hafyera is the 6-month formulation, administered twice a year for ultra-long-term maintenance.
• Sequence for Initiating LAI Therapy1. Confirm the diagnosis of schizophrenia and identify partial or full oral non-adherence.

  • 1. Confirm the diagnosis of schizophrenia and identify partial or full oral non-adherence.
  • 2. Administer an oral trial of the target agent to verify tolerability and rule out severe adverse reactions.
  • 3. Calculate the loading and maintenance dose per manufacturer guidelines.
  • 4. Administer the intramuscular injection using z-track technique into the deltoid or gluteal muscle.
  • 5. Provide oral overlapping coverage during the initiation phase as required by the specific drug kinetics.
• Common Board Traps and Distractor LogicThe Clozapine Shortcut Trap

  • The Clozapine Shortcut Trap
  • Why it looks right: Clozapine is the most effective antipsychotic for severe illness.
  • Why it is wrong: Clozapine requires strict ANC monitoring, carries risks of agranulocytosis, myocarditis, and severe constipation, and is reserved for treatment resistance, not unconfirmed oral adherence.
  • Board rule to remember: Fix non-adherence with an LAI before labeling a patient as treatment-resistant.
  • Skipping the Oral Trial
  • Why it looks right: The patient is acutely psychotic in the ED and needs immediate long-acting control.
• Genetic risk hierarchySchizophrenia genetic risk scales directly with genetic proximity: monozygotic twins share a 50% risk, offspring of two affected parents face a 40% risk, offspring of one parent face a 12% risk, non-twin siblings face an 8% risk, and the general population prevalence is 0.7%.

  • Schizophrenia genetic risk scales directly with genetic proximity: monozygotic twins share a 50% risk, offspring of two affected parents face a 40% risk, offspring of one parent face a 12% risk, non-twin siblings face an 8% risk, and the general population prevalence is 0.7%.
  • Diagnostic criteria require at least two characteristic symptoms for at least one month, with total continuous disturbance lasting at least six months; at least one symptom must be delusions, hallucinations, or disorganized speech.
  • First-line pharmacotherapy consists of second-generation antipsychotics (SGAs) due to lower extrapyramidal symptom (EPS) risk, comparable positive symptom efficacy, and superior action on negative symptoms via serotonin 5-HT2A receptor antagonism.
  • Clozapine is third-line for treatment-resistant cases, persistent suicidality, or severe aggression; initiation requires an absolute neutrophil count (ANC) of at least 1500 per cubic millimeter, with monthly monitoring after one year, and discontinuation if ANC falls below 1000.
  • Tobacco smoke byproducts induce the CYP1A2 isoenzyme, reducing blood levels of clozapine and olanzapine; smoking cessation leads to toxic drug accumulation, whereas resuming smoking drops therapeutic levels and triggers psychotic relapse.

  Board trap. Tobacco smoke byproducts induce the CYP1A2 isoenzyme, reducing blood levels of clozapine and olanzapine; smoking cessation leads to toxic drug accumulation, whereas resuming smoking drops therapeutic levels and triggers psychotic relapse.

  Safety. Neuroleptic Malignant Syndrome (NMS) presents as "hot, stiff, and out of it" with severe muscle rigidity, hyperthermia, altered consciousness, autonomic instability, and elevated serum creatine kinase (CK) above 1000 IU/L; immediate treatment requires drug cessation, supportive c

• Genetic Risk Hierarchy and EtiologyRisk scales directly with genetic proximity. Monozygotic twins demonstrate a 50% risk, which also means a 50% chance of no disease, proving non-genetic environmental factors exist.

  • Risk scales directly with genetic proximity. Monozygotic twins demonstrate a 50% risk, which also means a 50% chance of no disease, proving non-genetic environmental factors exist.
  • Offspring of two parents with schizophrenia carry a 40% risk (and a 60% chance of remaining unaffected). Offspring of one affected parent carry a 12% risk.
  • Non-twin siblings carry an 8% risk. The general population prevalence is 0.7%, affecting men and women equally across all cultures and geographic areas.
  • Men experience earlier peak onset between ages 10 and 25. Women experience peak onset between ages 25 and 35, with a minor second peak after age 40. Women generally exhibit better social functioning and fewer negative symptoms.
  • Perinatal and environmental risk factors include birth in winter or spring, maternal influenza exposure, maternal starvation during pregnancy, perinatal hypoxia, advanced paternal age, and obstetric complications.
  • Etiology involves multi-system neurochemical dysregulation across dopamine, glutamate, GABA, acetylcholine, nicotine, norepinephrine, and serotonin. No single brain region or single neurotransmitter accounts for the disorder.
• Medical Rule-Outs and Differential DiagnosticsAlways rule out physical disease, toxicities, and medication effects before diagnosing primary schizophrenia.

  • Always rule out physical disease, toxicities, and medication effects before diagnosing primary schizophrenia.
  • Medical substances causing psychotic symptoms include corticosteroids, anabolic steroids, cimetidine, disulfiram, amphetamines, cocaine, and withdrawal from alcohol or barbiturates.

  Safety. Organic conditions mimicking psychosis include neurodegenerative diseases (Alzheimer disease, Parkinson disease, Huntington disease, multiple sclerosis), CNS lesions (temporal lobe epilepsy, neoplasms, head trauma), vascular disease (hypertensive encephalopathy), infections (neur

• Board Pearls and PsychopharmacologySGAs (such as risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone) are preferred over FGAs (such as haloperidol, fluphenazine, chlorpromazine) due to reduced risk of EPS and tardive dyskinesia.

  • SGAs (such as risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone) are preferred over FGAs (such as haloperidol, fluphenazine, chlorpromazine) due to reduced risk of EPS and tardive dyskinesia.
  • FGAs block dopamine D2 receptors aggressively, causing high rates of acute dystonia, parkinsonism, and akathisia. Dystonia requires immediate treatment with parenteral benztropine or diphenhydramine. Akathisia responds best to propranolol.
  • Tardive dyskinesia presents with involuntary choreoathetoid movements of the face, tongue, and extremities. Screen using the Abnormal Involuntary Movement Scale (AIMS). Treat by switching to clozapine or quetiapine, or adding a VMAT2 inhibitor like valbenazine.
  • Clozapine carries black box warnings for agranulocytosis, severe constipation leading to bowel obstruction, myocarditis, seizures, and orthostatic hypotension. Monitor ANC weekly for 6 months, biweekly for 6 months, then monthly.

  Board trap. FGAs block dopamine D2 receptors aggressively, causing high rates of acute dystonia, parkinsonism, and akathisia. Dystonia requires immediate treatment with parenteral benztropine or diphenhydramine. Akathisia responds best to propranolol.

  Safety. NMS mortality reaches 10% to 20%. Characterized by hyperthermia, "lead-pipe" muscle rigidity, autonomic instability, and serum creatine kinase (CK) above 1000 IU/L. Discontinue offending psychotropics immediately and transfer to an intensive care unit for hydration and dantrolene

• Key ClueA: True statement. Agitation or command hallucinations in untreated psychosis can lead to violent outbursts.

  • A: True statement. Agitation or command hallucinations in untreated psychosis can lead to violent outbursts.
  • B: True statement. Co-occurring major depressive disorder is present in up to 80 percent of patients and markedly increases suicide risk.
  • C: True statement. Suicide is attempted by 20 to 50 percent of individuals diagnosed with schizophrenia.
• A, B, and D (Delusions, Hallucinations, Disorganized speech)C: Compulsive behaviors belong to obsessive-compulsive disorder criteria and are not a defining Criterion A feature of schizophrenia.

  • C: Compulsive behaviors belong to obsessive-compulsive disorder criteria and are not a defining Criterion A feature of schizophrenia.
• Etiological risk factors1. General population prevalence: Schizophrenia affects 0.7% of the population worldwide, occurring in equal proportions among men and women.

  • 1. General population prevalence: Schizophrenia affects 0.7% of the population worldwide, occurring in equal proportions among men and women.
  • 3. Age of onset divergence: Peak onset for men is 10 to 25 years of age, whereas peak onset for women is 25 to 35 years of age with a secondary smaller peak occurring after age 40 years. Onset is rare before age 10 years or after age 60 years.
  • 4. Environmental and gestational risk factors: Risk is significantly increased by winter and spring birth seasons, prenatal exposure to influenza, perinatal hypoxia, maternal starvation during pregnancy, and greater paternal age at conception.
  • 5. Neurochemical etiology: Schizophrenia is a complex biological brain disease involving multi-pathway neurotransmitter dysregulation across dopamine, serotonin, glutamate, GABA, acetylcholine, nicotine, and norepinephrine.
  • 6. Disproven etiology myths: The "schizophrenic-genic mother" theory is completely disproven. Psychosocial stress alters disease progression and triggers relapse, but does not cause the underlying biological pathology.
  • 7. Mortality and comorbidity: Life expectancy is reduced by up to 20% (dying up to 25 years earlier), driven heavily by tobacco addiction (90% prevalence) and cardiovascular comorbidities. Suicide is attempted by 20% to 50% of patients, with a 5% long-term completed suicide rate.
• Biological and Genetic Risk HierarchyWhat it is: Schizophrenia is a biological, neurodevelopmental brain disorder with a strong multifactorial genetic basis.

  • What it is: Schizophrenia is a biological, neurodevelopmental brain disorder with a strong multifactorial genetic basis.
  • Why boards care: ANCC and AANPCB exams test precise genetic concordance percentages, age of onset gender splits, and lifespan boundaries to differentiate biological facts from outdated clinical myths.
  • General population prevalence: 0.7%.
  • Gender ratio: Men equal women in overall prevalence.
  • Age of onset: Peak for men is 10 to 25 years of age. Peak for women is 25 to 35 years of age, with a secondary peak after age 40 years. Onset before age 10 years or after age 60 years is extremely rare.
  • Genetic concordance rates:

  Board trap. Do not select poor parenting, family communication styles, or "schizophrenic-genic mothers" as the etiology. Although pathologic family behaviors increase emotional stress and relapse risk, the illness is strictly biological.

  Safety. Suicide risk is extremely high. Lifetime suicide attempts occur in 20% to 50% of patients, with 5% completing suicide. Co-occurring major depressive disorder (occurring in up to 80% of patients over their lifetime) significantly elevates suicide attempt risk.

• Environmental, Prenatal, and Perinatal Risk FactorsWhat it is: Non-genetic gestational and environmental insults that impair fetal neurodevelopment and early brain formation.

  • What it is: Non-genetic gestational and environmental insults that impair fetal neurodevelopment and early brain formation.
  • Why boards care: Board questions evaluate recognition of non-hereditary risk factors that increase vulnerability to psychotic spectrum disorders.
  • Season of birth: Statistically increased incidence among individuals born in winter and spring months.
  • Gestational infection: Fetal exposure to maternal influenza during pregnancy.
  • Obstetric complications: Perinatal hypoxia, birth complications, and maternal starvation during pregnancy.
  • Demographics: Greater paternal age at the time of conception.

  Safety. Non-tobacco substance use disorder occurs in 50% of patients and alcohol use disorder in 40%, heavily triggering psychotic relapses and treatment non-adherence.

• Neurochemical and Neuroanatomical EtiologyWhat it is: Widespread dysregulation across central neurotransmitter networks without a single isolated anatomical lesion.

  • What it is: Widespread dysregulation across central neurotransmitter networks without a single isolated anatomical lesion.
  • Why boards care: Questions test the physiological basis of positive versus negative symptoms and the rationale for selecting second-generation antipsychotics.
  • Dopamine hypothesis: Mesolimbic pathway hyperactivity drives positive symptoms; mesocortical pathway hypoactivity drives negative and cognitive symptoms.
  • Serotonin dysregulation: Combined 5-HT2A receptor blockade in SGAs reduces extrapyramidal symptoms and improves negative symptoms.
  • Other neurotransmitters: Glutamate, GABA, acetylcholine, nicotine, and norepinephrine show widespread pathological alterations.
  • Compare and distinguish:

  • Positive symptoms vs Negative symptoms:
• High-yield board trapsAt least one active symptom must be delusions, hallucinations, or disorganized speech.

  • At least one active symptom must be delusions, hallucinations, or disorganized speech.
  • Illusions misinterpret actual external stimuli, whereas hallucinations occur with no external stimulus. Hypnagogic and hypnopompic hallucinations are normal sleep-wake transitions, not psychotic symptoms.
  • Visual hallucinations in an alert, elderly patient with vision loss (macular degeneration) and intact cognition represent Charles Bonnet syndrome, not late-onset schizophrenia.
  • Genetic concordance is highest in monozygotic twins at 50%. It drops to 40% if both parents have schizophrenia, 12% for one parent, and 8% for non-twin siblings.
  • Tobacco addiction affects 90% of individuals with schizophrenia. Hydrocarbon smoke byproducts induce CYP1A2, lowering blood levels of clozapine and olanzapine.
  • Neuroleptic Malignant Syndrome (NMS) presents with severe muscle rigidity, hyperthermia, autonomic instability, and altered consciousness. Serum creatine kinase (CK) spikes between 1,000 and 100,000 IU/L.

  Board trap. Illusions misinterpret actual external stimuli, whereas hallucinations occur with no external stimulus. Hypnagogic and hypnopompic hallucinations are normal sleep-wake transitions, not psychotic symptoms.

  Safety. Visual hallucinations in an alert, elderly patient with vision loss (macular degeneration) and intact cognition represent Charles Bonnet syndrome, not late-onset schizophrenia.

• Perceptual Distortions vs. Primary PsychosisHypnagogic hallucinations occur while falling asleep. Hypnopompic hallucinations occur while waking up. Both are normal physiological transitions and must never be diagnosed as schizophrenia.

  • Hypnagogic hallucinations occur while falling asleep. Hypnopompic hallucinations occur while waking up. Both are normal physiological transitions and must never be diagnosed as schizophrenia.

  Board trap. Do not confuse illusions with hallucinations. An illusion is a real sensory perception that is misinterpreted, such as mistaking a coat rack for an intruder in a dim room. A hallucination is a vivid, involuntary sensory perception occurring without any external stimulus. Auditory

• Medical Rule-Outs and Physical MimicsAlways complete a thorough medical evaluation for atypical presentations, new-onset symptoms after age 40, or sudden decompensation.

  • Always complete a thorough medical evaluation for atypical presentations, new-onset symptoms after age 40, or sudden decompensation.
  • Charles Bonnet syndrome: Occurs in elderly individuals with age-related macular degeneration, glaucoma, or diabetic retinopathy. Patients experience complex visual hallucinations while remaining alert, lucid, and cognitively intact with zero auditory hallucinations.
  • Central nervous system mimics include Huntington disease, multiple sclerosis, Parkinson disease, temporal lobe epilepsy, head trauma, and CNS neoplasms.
  • Infectious and metabolic mimics include neurosyphilis, HIV encephalopathy, herpes encephalitis, Creutzfeldt-Jakob disease, hyponatremia, hypercalcemia, B12 deficiency, thiamine deficiency, Addison disease, and Cushing syndrome.
  • Pharmacological mimics include corticosteroids, anabolic steroids, cimetidine, disulfiram, and sympathomimetic stimulants.

  Safety. Always complete a thorough medical evaluation for atypical presentations, new-onset symptoms after age 40, or sudden decompensation.

• Etiology and NeurobiologySecond-generation antipsychotics (SGAs) combine D2 receptor antagonism with 5-HT2A serotonin antagonism, delivering superior efficacy for negative symptoms compared to first-generation antipsychotics (FGAs).

  • Etiology is unknown but represents a brain-based biological illness with multifactorial origin.
  • Winter and spring birth dates correlate with higher incidence due to perinatal viral exposure, maternal starvation, or hypoxia.
  • Neurotransmitter dysregulation involves dopamine, glutamate, GABA, acetylcholine, nicotine, serotonin, and norepinephrine.
  • Second-generation antipsychotics (SGAs) combine D2 receptor antagonism with 5-HT2A serotonin antagonism, delivering superior efficacy for negative symptoms compared to first-generation antipsychotics (FGAs).
• Violence, Suicide, and Homicide FactsMedicated patients with schizophrenia are no more likely to commit homicide than the general public.

  • Medicated patients with schizophrenia are no more likely to commit homicide than the general public.
  • Violence in schizophrenia is a complication of non-treatment, acute agitation, or command hallucinations. Patients are far more likely to be victims of violence than perpetrators.
  • Suicide is attempted by 20% to 50% of patients, with a 5% long-term completion rate. Risk peaks during co-occurring major depressive disorder episodes, command hallucinations, substance misuse, or high insight into disease limitations.

  Board trap. Medicated patients with schizophrenia are no more likely to commit homicide than the general public.

• Pharmacokinetics and Clozapine SafetyTobacco smoke byproducts induce the CYP1A2 isoenzyme. This accelerates the clearance of clozapine and olanzapine. Smoking cessation or inpatient non-smoking status causes serum drug levels to surge, increasing toxicity risk.

  • Tobacco smoke byproducts induce the CYP1A2 isoenzyme. This accelerates the clearance of clozapine and olanzapine. Smoking cessation or inpatient non-smoking status causes serum drug levels to surge, increasing toxicity risk.
  • Clozapine carries a risk of life-threatening agranulocytosis in 1% to 2% of patients. Initiate therapy only if ANC is 1,500/mm3 or greater. Monitor ANC weekly for 6 months, biweekly for 6 months, then monthly. Interrupt treatment if ANC drops below 1,000/mm3.
  • Clozapine also carries a severe risk for anticholinergic constipation leading to small bowel obstruction, requiring a prophylactic bowel regimen.

  Board trap. Tobacco smoke byproducts induce the CYP1A2 isoenzyme. This accelerates the clearance of clozapine and olanzapine. Smoking cessation or inpatient non-smoking status causes serum drug levels to surge, increasing toxicity risk.

  Safety. Clozapine carries a risk of life-threatening agranulocytosis in 1% to 2% of patients. Initiate therapy only if ANC is 1,500/mm3 or greater. Monitor ANC weekly for 6 months, biweekly for 6 months, then monthly. Interrupt treatment if ANC drops below 1,000/mm3.

• Fitzgerald Sample Question 7Prevalence and Onset: Schizophrenia affects 0.7% of the general population equally between genders (1:1 ratio). Peak onset in males is 10 to 25 years, whereas peak onset in females is 25 to 35 years with a secondary peak after age 40 years.

  • Prevalence and Onset: Schizophrenia affects 0.7% of the general population equally between genders (1:1 ratio). Peak onset in males is 10 to 25 years, whereas peak onset in females is 25 to 35 years with a secondary peak after age 40 years.
  • Genetics and Etiology: Monozygotic twin concordance is 50%, proving that non-genetic factors play an equal role. Risk is 40% if both parents have schizophrenia, 12% if one parent is affected, and 8% for non-twin siblings.
  • Pharmacokinetics of Smoking: Hydrocarbon byproducts in tobacco smoke induce the CYP1A2 enzyme, lowering serum concentrations of clozapine and olanzapine. Patients who stop smoking abruptly while hospitalized experience elevated drug levels and severe toxicity risks.
  • Diagnostic Criteria: Requires at least 2 characteristic symptoms for a 1-month active phase (at least 1 must be delusions, hallucinations, or disorganized speech), with continuous signs of disturbance persisting for at least 6 months.
  • Suicide Risk: 20% to 50% of patients with schizophrenia attempt suicide, and 5% die by suicide. Risk peaks during co-occurring major depressive disorder episodes, periods following hospital discharge, and when patients gain insight into their functional impairment.
• Schizophrenia Etiology and Risk HierarchyBiopsychosocial Model: Schizophrenia is a neurodevelopmental brain disorder caused by polygenic vulnerability interacting with environmental stressors.

  • Biopsychosocial Model: Schizophrenia is a neurodevelopmental brain disorder caused by polygenic vulnerability interacting with environmental stressors.
  • Perinatal Risk Factors: Birth during winter and spring correlates with higher risk due to seasonal influenza exposure, maternal malnutrition, fetal hypoxia, and advanced paternal age.
  • Neurotransmitter Dysregulation: Involves mesolimbic dopamine hyperactivity (causing positive symptoms), mesocortical dopamine hypoactivity (causing negative and cognitive symptoms), serotonin 5-HT2A dysregulation, glutamate NMDA receptor hypofunction, and GABA deficits.
• Medical Rule-Outs and Differential DiagnosisNeurologic Mimics: Huntington's disease, Parkinson's disease, Alzheimer's disease, Lewy body dementia, temporal lobe epilepsy, CNS neoplasms, and traumatic brain injury.

  • Neurologic Mimics: Huntington's disease, Parkinson's disease, Alzheimer's disease, Lewy body dementia, temporal lobe epilepsy, CNS neoplasms, and traumatic brain injury.
  • Infectious and Vascular Causes: Neurosyphilis, HIV encephalopathy, herpes encephalitis, Creutzfeldt-Jakob disease, and hypertensive encephalopathy.
  • Endocrine and Metabolic Derangements: Uremia, hyponatremia, hypoglycemia, Addison's disease, Cushing's syndrome, and thyroid storm or severe hypothyroidism.
  • Nutritional and Substance Mimics: Vitamin B12 deficiency, thiamine deficiency (Wernicke-Korsakoff), folate deficiency, corticosteroids, anabolic steroids, cimetidine, disulfiram, and heavy metal toxicity (lead, mercury, arsenic).
• Perceptual Disturbance ClassificationIllusion: Misperception of a real sensory input. An external object exists, but the brain misinterprets its identity.

  • Illusion: Misperception of a real sensory input. An external object exists, but the brain misinterprets its identity.
  • Hallucination: Perception of a sensory phenomenon when no external stimulus exists. Can be auditory (most common), visual, tactile, olfactory, or gustatory.
  • Delusion: False, fixed belief that cannot be corrected by logical reasoning or evidence to the contrary.
  • Derealization: Subjective feeling that the surrounding environment is unreal, distant, or artificial, without misidentifying specific physical objects.
• Signposts: Safety Alerts, Board Traps, and First-Line StandardsSGAs (second-generation antipsychotics) are first-line treatment for schizophrenia because of lower EPS and tardive dyskinesia risks and superior action against negative symptoms via serotonin 5-HT2A receptor antagonism.

  • Abrupt smoking cessation in a patient taking clozapine or olanzapine removes CYP1A2 induction, causing blood levels to spike rapidly into toxic ranges. Monitor serum concentrations closely and reduce doses when patients enter smoke-free facilities.
  • Suicide risk is exceptionally high in schizophrenia when patients experience co-occurring major depressive disorder, active command hallucinations, or restored insight into the chronic limitations of their illness.
  • Do not confuse an illusion with a hallucination on exam stems. Check whether a real physical object is present in the patient's environment. If the stem mentions an object (like ceiling shadows, a coat rack, or a rustling curtain), the misperception is an illusion.
  • Exam writers test genetics by asking about twin concordance. Monozygotic twin concordance is 50%, which means there is also a 50% chance the twin will not develop schizophrenia.
  • SGAs (second-generation antipsychotics) are first-line treatment for schizophrenia because of lower EPS and tardive dyskinesia risks and superior action against negative symptoms via serotonin 5-HT2A receptor antagonism.
  • Clozapine is the gold-standard third-line agent for treatment-resistant schizophrenia (failing 2 adequate trials of antipsychotics) and for reducing persistent suicidal or homicidal behavior.

  Board trap. Do not confuse an illusion with a hallucination on exam stems. Check whether a real physical object is present in the patient's environment. If the stem mentions an object (like ceiling shadows, a coat rack, or a rustling curtain), the misperception is an illusion.

  Safety. Abrupt smoking cessation in a patient taking clozapine or olanzapine removes CYP1A2 induction, causing blood levels to spike rapidly into toxic ranges. Monitor serum concentrations closely and reduce doses when patients enter smoke-free facilities.